 I. To observe and record anti-tumor activity. II. To establish the pharmacokinetics of daily po dosing of IPdR x 28 days. III. To assess, for patients treated at the MTD, for biochemical evidence of IPdR effect in normal tissue circulating granulocytes and tumor tissue in patients with accessible tumor tissue by measuring iododeoxyuridine IUdR-deoxyribonucleic acid DNA cellular incorporation by flow cytometry and high-pressure liquid chromatography HPLC analyses. 